Last updated: 2026-09-04 21:28:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Neuronetics, Inc. (STIM) operates in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector and is listed on NASDAQ. The stock is currently priced at $2,89, with a market capitalization of $211,07M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $0,80 to $3,71. This page covers its latest market performance, valuation, price trends and company information.
$211,07M | |
$2,72 | |
$39,39 | |
$0,52 | |
$2,72 | |
978,10K | |
-- | |
-- | |
$3,71 | |
$0,80 | |
0,09% | |
-- |
Neuronetics, Inc. (STIM) is trading at $2,89 in after-hours trading as of 2026-09-04 20:32:00, up 6,07% ($0,16) from the regular-session close of $2,72.
After-hours trading shows how investors are pricing STIM after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Neuronetics, Inc. (STIM) moved from $2,95 to $2,89, representing a decline of 2,20% ($0,07).
The stock traded between $2,68 and $2,97 during the period. The latest price is near the upper end of the 7-day range, indicating moderate downward.
The average daily volume was 880,08 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 71,6%
STIM is currently trading at $2,89, placing it 71,6% of the way from its 52-week low of $0,80 to its 52-week high of $3,71. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
| Industry | SURGICAL & MEDICAL INSTRUMENTS & APPARATUS |
| Employees | 658 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Neuronetics, Inc. (STIM) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.